Editas Medicine (EDIT) Posts Q1 GAAP Loss of 80c/Share

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.80), which may not compare with the analyst estimate of ($0.30). Revenue for the quarter came in at $805 thousand versus the consensus estimate of $1.08 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Wells Fargo previews Q2 midstream earnings, favors PAA and TRGP
• Morgan Stanley Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to Equalweight